Genetically engineered mouse model of pleomorphic liposarcoma: Immunophenotyping and histologic characterization.

Area of Science:

• Oncology
• Genetics
• Immunology

Background:

• Pleomorphic liposarcoma is a rare, aggressive soft-tissue sarcoma with limited systemic treatment options.
• Existing experimental models have limitations in fully recapitulating the disease.
• Novel therapeutic strategies require more accurate preclinical models.

Purpose of the Study:

• To establish a reliable, immunocompetent genetically engineered mouse model for pleomorphic liposarcoma.
• To characterize the tumor microenvironment and immunological features of this model.
• To assess the potential utility of this model for preclinical therapeutic testing.

Main Methods:

• Conditional silencing of Trp53, Rb1, and Pten tumor suppressor genes in mice (RPP mice) using Cre-mediated recombination.
• Histological evaluation of tumor development and characteristics.
• Immunoprofiling using immunostaining and flow cytometry to analyze tumor-infiltrating lymphocytes (TILs).

Main Results:

• RPP mice reliably developed soft-tissue tumors consistent with pleomorphic liposarcoma within approximately 6 weeks.
• Tumor growth was rapid, with mice reaching euthanasia criteria between 100 and 150 days.
• Immunoprofiling revealed TIL populations similar to those observed in other soft-tissue sarcomas.

Conclusions:

• Genetically engineered RPP mice provide a reliable model for pleomorphic liposarcoma.
• The model exhibits immunological characteristics relevant to human disease.
• This immunocompetent model holds potential for evaluating novel treatments, particularly immunotherapies, for pleomorphic liposarcoma.